In addition, two of four previous trials in humans suggested modest benefits in crisis control and good tolerability, without experiencing adverse effects or experiencing mild effects. However, these trials were too small (between 9 and 15 patients) to adequately evaluate their efficacy.
Pre-clinical and clinical insufficient data, in addition to the anecdotal reports of recent years, have been crossed with the need for more effective therapies for treatment-resistant epilepsy, creating a demand from patients and their families for access to treatments based on cannabidiol. Visit More https://foodsocietyx.com/sera-labs-cbd-oil-reviews
No comments:
Post a Comment